High grade breast ductal carcinomas have high density of tumor-associated macrophages.

Q3 Medicine Experimental oncology Pub Date : 2021-12-01 DOI:10.32471/exp-oncology.2312-8852.vol-43-no-4.16898

Ata Abbasi, Sepideh Rahimi, Leila Mahmoudzadeh, Hengameh Mojdeganlou

{"title":"High grade breast ductal carcinomas have high density of tumor-associated macrophages.","authors":"Ata Abbasi, Sepideh Rahimi, Leila Mahmoudzadeh, Hengameh Mojdeganlou","doi":"10.32471/exp-oncology.2312-8852.vol-43-no-4.16898","DOIUrl":null,"url":null,"abstract":"Background: The role of tumor-associated macrophages (TAMs) is double-natured and still controversial. Depending on different settings, macrophages may suppress or promote tumor growth. TAM density may be one of the predictive factors of treatment outcome in cancer patients.Aim: To evaluate the density of tumor-associated macrophages in breast cancer and its relationship with various histopathologic findings.Materials and methods: 55 patients with invasive ductal carcinoma of breast who underwent mastectomy were enrolled. Sections of tumor samples were stained and the density of CD68+ cells was evaluated.Results: There was an association between estrogen receptor (ER) expression and CD68 density (p = 0.010) as the higher densities of CD68 were seen in ER negative tumors. Moreover, there was a significant relationship between histological grade and CD68 density (p = 0.006).Conclusion: The higher TAM density is associated with higher tumor grade and negative ER expression in breast cancer tissues. These findings revealed that inflammation could have an important role in malignancies.","PeriodicalId":12287,"journal":{"name":"Experimental oncology","volume":"43 4","pages":"328-330"},"PeriodicalIF":0.0000,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Experimental oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32471/exp-oncology.2312-8852.vol-43-no-4.16898","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The role of tumor-associated macrophages (TAMs) is double-natured and still controversial. Depending on different settings, macrophages may suppress or promote tumor growth. TAM density may be one of the predictive factors of treatment outcome in cancer patients.

Aim: To evaluate the density of tumor-associated macrophages in breast cancer and its relationship with various histopathologic findings.

Materials and methods: 55 patients with invasive ductal carcinoma of breast who underwent mastectomy were enrolled. Sections of tumor samples were stained and the density of CD68⁺ cells was evaluated.

Results: There was an association between estrogen receptor (ER) expression and CD68 density (p = 0.010) as the higher densities of CD68 were seen in ER negative tumors. Moreover, there was a significant relationship between histological grade and CD68 density (p = 0.006).

Conclusion: The higher TAM density is associated with higher tumor grade and negative ER expression in breast cancer tissues. These findings revealed that inflammation could have an important role in malignancies.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

高级别乳腺导管癌具有高密度的肿瘤相关巨噬细胞。

背景:肿瘤相关巨噬细胞(tam)的作用是双重性质的，目前仍有争议。根据不同的环境，巨噬细胞可以抑制或促进肿瘤的生长。TAM密度可能是癌症患者治疗结果的预测因素之一。目的:探讨乳腺癌组织中肿瘤相关巨噬细胞的密度及其与各种病理组织学表现的关系。材料与方法:选取55例行乳房切除术的浸润性乳腺导管癌患者。对肿瘤切片进行染色，评估CD68+细胞密度。结果:雌激素受体(ER)表达与CD68密度呈正相关(p = 0.010)， ER阴性肿瘤中CD68密度较高。此外，组织学分级与CD68密度之间存在显著相关性(p = 0.006)。结论:乳腺癌组织中TAM密度越高，肿瘤分级越高，ER表达越阴性。这些发现表明炎症可能在恶性肿瘤中起重要作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Experimental oncology Medicine-Oncology

CiteScore

1.40

自引率

0.00%

发文量

期刊介绍： The Experimental Oncology is an English-language journal that publishes review articles, original contributions, short communications, case reports and technical advances presenting new data in the field of experimental and fundamental oncology. Manuscripts should be written in English, contain original work, which has not been published or submitted for publication elsewhere. It also implies the transfer of the Copyright from the author to “Experimental Oncology”. No part of journal publications may be reproduced, stored in a retrieval system or transmitted in any form or by any means without the prior permission of the publisher.